Bio: Dr. Rong Kuang is the Director of the Pharmacology and Toxicology Research Institute at the Zhejiang Institute for Food and Drug Control and the Director of the Center for Drug Safety Evaluation. He holds multiple prominent roles, including membership in the NMPA Pharmacopoeia Committee and the Cosmetics Standardization Technical Committee and serves as the Director of the Key Laboratory of Animal Alternative Test Technology for Cosmetics. He is also a recognized expert in GLP certification and cosmetics toxicology evaluation. Dr. Kuang specializes in drug inspection and the safety evaluation of food, drugs, and cosmetics. In recent years, he has focused on advancing animal alternative technologies in China, successfully integrating methods such as the BCOP test into the country’s cosmetics safety technical specifications. Currently, he is leading a team to prepare for GIVIMP (Good In Vitro Method Practices) certification and validate organ-on-a-chip technology for liver toxicity assessment.

Abstract: The application of the “Guidance Document on Good In Vitro Method Practices (GIVIMP)” principles in a laboratory in China represents a significant step toward enhancing the reliability and global acceptance of in vitro methodologies. GIVIMP, developed by the Organisation for Economic Co-operation and Development (OECD), provides a comprehensive framework for ensuring the quality, reproducibility, and ethical integrity of in vitro studies. In China, where the adoption of New Approach Methodologies (NAMs) is gaining momentum, implementing GIVIMP principles can address critical challenges such as standardization, validation, and data transparency. This study explores the practical application of GIVIMP in a Chinese laboratory, focusing on areas such as protocol optimization, quality control, staff training, and the integration of advanced technologies like artificial intelligence. By aligning with GIVIMP, the laboratory not only improves the robustness of its in vitro data but also strengthens its credibility in international collaborations and regulatory submissions. The findings highlight the transformative potential of GIVIMP in advancing China's role in global toxicology research, while also identifying challenges such as resource constraints and the need for cultural adaptation. This case study underscores the importance of adopting globally harmonized practices to foster innovation and trust in in vitro methodologies, positioning China as a leader in the evolving landscape of chemical safety assessment.